Hosted on MSN4h
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
dvm3608d
Treatment options for mild atopic dermatitis
In this Q&A, Marty Becker, DVM, Elite FFCP-V and Paul Bloom, DVM, DACVD, DABVP (Canine and Feline), Elite FFCP-III share ...
Daily1d
Once-Daily Roflumilast Cream Shows Promising for Atopic Dermatitis: JAMA
A 0.15% once-daily roflumilast cream improved symptoms of atopic dermatitis (AD) across multiple endpoints, according to ...
Pharmabiz3d
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...
Future Market Insights10d
Global Atopic Dermatitis Treatment Market Poised for Significant Growth, Projected to Reach USD 45,501.6 Million by 2034 at a CAGR of 11.7%
The global atopic dermatitis treatment market is on the cusp of remarkable expansion, with projections indicating a surge in ...
Medscape2d
Pause Immunosuppressants Prior to Patch Testing If Possible
Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...
Daily4d
Upadacitinib Shows Long-Term Success in the Treatment of Atopic Dermatitis, finds study
A recent study published in the Dermatology and Therapy journal confirmed the effectiveness and safety of upadacitinib, a ...
BizWest7d
Enveda: Dermatitis drug candidate could help treat asthma
Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, plans to begin testing ENV-294, its leading drug candidate developed to treat atopic ...
Business Wire1d
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for Treating Metabolic Dysfunction-Associated Steatohepati…
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...
Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe Atopic Dermatitis And Prurigo N...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...